Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
GLP-1s, however, may also exert direct hormonal effects as GLP-1 receptors can be found across the hypothalamus-pituitary-ovarian (HPO) axis and influence gonadotropin release and follicle development
2 way Dual Activation GHRH-R (CJC-1295) + GHS-R1a (Ipamorelin) two complementary pituitary targets 2-4x GH AUC Demonstrated Synergy Area under the GH curve 2 to 4 times greater than each peptide in monotherapy 5.8 - 8.1 days CJC-1295 Half-Life Sustained elevation of IGF-1 for 9 to 11 days after a single injection 10 mg Pre-formulated mix 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin per vial | Purity 99% HPLC Selective Hormonal Profile Ipamorelin: no increase in cortisol, prolactin or ACTH (Raun et al., 1998) Mechanism of Action Dual-Channel Synergy Simultaneous activation of GHRH-R and GHS-R1a for amplified GH stimulation GHRH Lane CJC-1295 GHRH Analog (Mod GRF 1-29) A synthetic peptide of 29 amino acids that selectively binds to the GHRH receptor on pituitary somatotroph cells
Read our February 2026 update on Canadian drug importation to see how these issues have evolved
Eli Lillys orforglipron, however, would be the first next-generation GLP-1 pill for weight loss if approved
Study shows a tenfold increase in the number of users of new diabetes medication
A mean weight loss of 13.7% is seen with a target dose of 2.4 mg biweekly and 9.0% with a target dose of 1.8 mg biweekly
